ARCA Biopharma Inc ABIO

Healthcare Biotechnology

ARCA biopharma, Inc. is a clinical-stage biopharmaceutical company engaged in developing genetically and other targeted therapies for cardiovascular diseases through a precision medicine approach to drug development. The Company's lead product candidate is Gencaro (bucindolol hydrochloride) for the treatment of atrial fibrillation (AF) in patients with chronic heart failure (HF). Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy. Gencaro is a pharmacogenetically-targeted beta-adrenergic receptor antagonist with mild vasodilator properties that is developing for the treatment of atrial fibrillation in patients with heart failure. Its Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), is a protein therapeutic in clinical development as a potential treatment for patients with COVID-19. It is also evaluating options for development of its assets, including partnering and other strategic options.

NDAQ:ABIO - Post by User

ARCA Biopharma Inc

Bullboard Posts

Comment by bullorbear22on Jul 05, 2009 5:04pm

463 Views

Post# 16118051

RE: Upcoming Phase 3 data of Obesity drug

Thanks good to know.

I also hold a Jr Pharma named Pharmagap Inc.

I’m a shareholder trying to create greater exposure etc.

Interesting story, good board & market, upcoming news etc.

The US National Cancer Institute is testing their lead drug on human cancer cells, and the results could be as good as the 2008 results that were 80% effective with animals, should the company receive the same results the share price could move significantly.

Bullboard Posts

How to interpret movements in the price of gold